Matthew D Neal: Most of the World is a “Platelet Desert” – Which Innovations in Platelet Transfusion Will Be an Oasis, and Which are a Mirage?
Matthew D Neal, Associate Professor of Surgery, Critical Care Medicine, and Clinical and Translational Science at University of Pittsburgh School of Medicine, shared on LinkedIn:
“Most of the world is a ‘platelet desert.’ Access to lifesaving platelet transfusions is lacking not only in low- and middle-income countries but also in major cities in the United States due to donor shortages and storage limitations. Rural areas have little to no available platelets, and platelets are absent from prehospital care where timely transfusion can save lives.
It was a pleasure to write this editorial for JAMA with Phil Spinella and Lucy Zumwinkle Kornblith. Here, we review the CLIP-II results and we tackle a challenging question –> which innovations in platelet transfusion will be an oasis, and which are a mirage?
Title: Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial
Authors: Michael C. Reade, Denese C. Marks, Belinda D. Howe, Michael J. Bailey, Paul G. Bannon, Glenn M. Eastwood, Craig J. French, David J. Gattas, Alisa M. Higgins, Anthony D. Holley, Raymond T. Hu, David O. Irving, Lacey Johnson, Shay P. McGuinness, Zoe K. McQuilten, Alistair G. Royse, Julian A. Smith, Laurence Weinberg, Erica M. Wood, the Cryopreserved vs Liquid Platelets II (CLIP-II) Investigators, the Australian and New Zealand Intensive Care Society Clinical Trials Group, the Australian and New Zealand College of Anaesthetists Clinical Trials Network, the Australasian Society of Cardiac and Thoracic Surgeons

Our editorial can be found here.
Title: An Oasis in the Platelet Desert?
Authors: Matthew D Neal, Philip C. Spinella, Lucy Z. Kornblith

Comments and questions are welcome! This is THE fastest and most innovative area of trauma and transfusion medicine research.”
Follow the latest in Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial